|
Gene: TAGAP |
Gene summary for TAGAP |
Gene summary. |
Gene information | Species | Human | Gene symbol | TAGAP | Gene ID | 117289 |
Gene name | T cell activation RhoGTPase activating protein | |
Gene Alias | ARHGAP47 | |
Cytomap | 6q25.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q8N103 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
117289 | TAGAP | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 1.29e-04 | 6.42e-01 | 0.159 |
117289 | TAGAP | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.53e-03 | 2.85e-01 | 0.1633 |
117289 | TAGAP | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.89e-05 | 3.75e-01 | 0.1621 |
117289 | TAGAP | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 2.91e-04 | 6.30e-01 | 0.159 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Prostate | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005105613 | Prostate | Tumor | regulation of small GTPase mediated signal transduction | 80/3246 | 302/18723 | 3.96e-05 | 4.57e-04 | 80 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAGAP | SNV | Missense_Mutation | c.1831G>A | p.Glu611Lys | p.E611K | Q8N103 | protein_coding | tolerated(0.82) | benign(0.007) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TAGAP | SNV | Missense_Mutation | rs778745747 | c.1874N>T | p.Ala625Val | p.A625V | Q8N103 | protein_coding | tolerated(0.1) | benign(0.052) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
TAGAP | SNV | Missense_Mutation | novel | c.839N>G | p.Asn280Ser | p.N280S | Q8N103 | protein_coding | deleterious(0.03) | benign(0.399) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TAGAP | SNV | Missense_Mutation | c.227C>A | p.Ala76Asp | p.A76D | Q8N103 | protein_coding | tolerated(0.13) | benign(0.153) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
TAGAP | SNV | Missense_Mutation | novel | c.1252N>A | p.Ala418Thr | p.A418T | Q8N103 | protein_coding | tolerated(0.42) | benign(0.005) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
TAGAP | SNV | Missense_Mutation | novel | c.761N>T | p.Ala254Val | p.A254V | Q8N103 | protein_coding | tolerated(0.55) | benign(0.081) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
TAGAP | SNV | Missense_Mutation | c.1452N>A | p.Phe484Leu | p.F484L | Q8N103 | protein_coding | tolerated(0.06) | benign(0.07) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TAGAP | SNV | Missense_Mutation | c.88N>G | p.Ile30Val | p.I30V | Q8N103 | protein_coding | tolerated(0.26) | benign(0.023) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
TAGAP | SNV | Missense_Mutation | rs181275709 | c.76N>C | p.Ser26Pro | p.S26P | Q8N103 | protein_coding | deleterious(0.04) | benign(0.087) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
TAGAP | SNV | Missense_Mutation | rs759308422 | c.2135G>A | p.Arg712Gln | p.R712Q | Q8N103 | protein_coding | tolerated(0.12) | benign(0.152) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |